The year health innovation has to prove its worth

Over the past decade, health, pharmaceuticals and digital care have evolved at pace. We have seen the emergence of advanced therapies, the rapid expansion of telehealth into a mainstream care channel, and the growing role of data and digital tools across diagnosis, treatment and patient support. New platforms, smarter tools and more personalised approaches have reshaped how care is delivered, accessed and understood.

As we look ahead to 2026, that progress continues, but expectations have changed. Innovation alone is no longer enough. Health systems, regulators, clinicians and patients are increasingly asking a harder question: does it work at scale, and can it be trusted?

Trends shaping healthcare, medicine and digital in 2026

Across healthcare, pharmaceuticals and digital, three shifts are becoming harder to ignore:

• Innovation is expected, not exceptional
• Trust is becoming a prerequisite for adoption
• Communications is moving from support function to strategic lever

FROM PILOTS TO PERFORMANCE

Health systems are under pressure from rising demand, workforce shortages and constrained funding. Over the past few years, many organisations have responded by testing new digital tools, platforms and models of care, such as remote monitoring programs, digital therapeutics, AI-enabled workflow tools or virtual care pathways.

What is driving the shift

Several factors are pushing organisations away from experimentation and towards performance:

• Multiple digital pilots with limited scale or integration
• Growing scrutiny on cost, workforce impact and measurable outcomes
• Pressure to demonstrate system-level value rather than isolated success

What decision-makers are now asking

In this environment, leaders are asking more practical and demanding questions:

• Does this reduce burden for clinicians?
• Does it improve patient understanding, experience or adherence?
• Can it scale across settings, systems and markets?

What successful innovation looks like in 2026

• Fewer pilots and more scaled solutions
• Clear return on investment and system impact
• Direct links between digital tools and real-world outcomes

This shift matters because it changes how innovation needs to be communicated. Broad ambition is no longer enough. Claims must be specific, evidence must be accessible, and benefits must be articulated in ways that resonate with different audiences, from policymakers to clinicians and patients.

 

AI’S REAL CHALLENGE IS NOT TECHNOLOGY, IT IS TRUST

Artificial intelligence has moved quickly from the margins to the centre of healthcare strategy. Over the past few years, AI has been applied across clinical decision support, workflow optimisation, data analysis and patient engagement. What was once experimental is now increasingly embedded in everyday practice.

What is changing in 2026

Several shifts are converging to raise the stakes for AI in health:

• AI is moving beyond back-end optimisation into decision-support and patient-facing contexts
• Consumer tools are increasingly interpreting personal health information, not just providing general education
• Expectations rise sharply when technology feels personalised, even when disclaimers are present

Recent developments such as OpenAI’s introduction of ChatGPT Health illustrate this broader shift. While positioned as informational rather than clinical, tools like this signal how AI is increasingly being used to help people make sense of health information in a more personal, contextual way.

Why trust becomes the gating factor

When AI operates closer to individual health decisions, tolerance for error drops. Simplification carries more risk. Users expect relevance, accuracy and transparency, even when systems are explicitly positioned as supportive rather than diagnostic.

In practice, this puts pressure on several areas at once:

• Data quality and governance, including how inputs are sourced and handled
• Explainability, particularly how outputs are generated and framed
• Boundaries and workforce confidence, ensuring clinicians understand, trust and appropriately use AI-enabled tools

In this environment, trust is no longer an abstract reputation issue. It directly affects adoption, compliance and outcomes.

What this means for health organisations

For healthcare, pharmaceutical and medtech organisations, the implication is clear. As AI becomes more visible and more personal, communication cannot sit behind the technology. It must actively shape how AI-enabled tools are understood.

 

PRICING, POLICY AND ACCESS: THE PRESSURE SHAPING EVERYTHING ELSE

Alongside technological change, pricing and policy pressures are increasingly shaping the healthcare and life sciences landscape. Decisions about access, affordability and reimbursement are becoming more visible, more contested and more closely scrutinised by governments, media, healthcare professionals and patients alike.

What is driving pricing and access uncertainty

As we move into 2026, pharmaceutical pricing and access are continuing to be shaped by a combination of global and local pressures, including:

•  Ongoing scrutiny of pharmaceutical pricing and affordability, including Most Favoured Nation models
• Pharmaceutical tariffs and shifting global trade dynamics
• Health technology assessment reform in Australia
• Increased scrutiny of PBAC processes
• Broader pressure on Medicare sustainability and value

Together, these forces are influencing launch sequencing, market prioritisation and investment decisions across markets.

Why this matters for communications

When access and pricing are in flux, silence creates risk.

Stakeholders, including clinicians, patient groups and the public, are looking for clarity. They want to understand not just what is available, but why decisions are made, when access may change and how constraints are being managed.

This puts pressure on communications teams to:

• Explain context without overpromising
• Navigate heightened sensitivity around affordability and value
• Maintain trust when answers are evolving or incomplete
• Support internal stakeholders with clear, defensible narratives

 

A NEW RELEVANCE TEST FOR HEALTH COMMUNICATIONS

As these trends converge, the way health information is discovered, interpreted and trusted is changing. Search, social and AI-mediated environments increasingly determine what information is surfaced, how it is framed and which sources are seen as credible.

In this context, reach alone is no longer the primary measure of influence. Health information is often summarised and interpreted before it is read directly, which places greater weight on clarity, structure and authority across all touchpoints.

Implications for communications strategies

For organisations operating in health, corporate reputation, product visibility and disease awareness are shaped by how information is surfaced and interpreted across discovery environments.

In practice, this means:

•  Ensuring information is clear, structured and interpretable in AI-mediated contexts
• Strengthening authoritative signals across corporate, product and disease narratives
• Increasing focus on earned media and third-party credibility, which increasingly influence AI outputs
• Embedding AIO and GEO considerations into content, reputation and communications planning

In 2026, effectiveness is defined less by how visible organisations are, and more by how accurately and consistently they are represented when information is interpreted on their behalf.

WHAT THIS MEANS FOR 2026

Taken together, these trends point to a more demanding health environment in 2026. Innovation is expected. What differentiates organisations is their ability to demonstrate value, build confidence and communicate clearly in conditions that are often uncertain.

The organisations that succeed will be those that recognise communications as a strategic capability. One that connects innovation to trust, and ambition to outcomes.

If you would like to explore what this means for your organisation or your audiences, get in touch with Cube to continue the conversation.

Get in touch

Authored by Bonnie Leibel, Senior Director

References

Deloitte, Global Healthcare and Life Sciences Outlooks (2026)
Wolters Kluwer, Healthcare AI Outlook (2026)
Definitive Healthcare, Healthcare Trends Report (2026)
Healthline Media, Health Consumer and Behaviour Insights